Blood Platelets

• 

  Subject Areas on Research

  • A Bigger Look Into the "Therapeutic Window" of Platelet Reactivity to Adenosine Diphosphate. 
  • A G-protein beta gamma-subunit-responsive phosphoinositide 3-kinase activity in human platelet cytosol. 
  • A Regenerative Cardiac Patch Formed by Spray Painting of Biomaterials onto the Heart. 
  • A Step toward Combined Platelet and Erythrocyte Recovery. 
  • A canine model of acute coronary artery thrombosis for the evaluation of reperfusion strategies. 
  • A cell-based model of coagulation and the role of factor VIIa. 
  • A cell-based model of hemostasis. 
  • A high-performance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A meta-analysis and genome-wide association study of platelet count and mean platelet volume in african americans. 
  • A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. 
  • A novel ultrasound-based method to evaluate hemostatic function of whole blood. 
  • A possible mechanism of action of activated factor VII independent of tissue factor. 
  • A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection. 
  • A radioreceptor assay for quantitating plasma factor VIII/von Willebrand's protein. 
  • A rapid method to isolate platelets from human blood by density gradient centrifugation. 
  • A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation. 
  • A thought experiment in contemporary drug development: informed bench-to-bedside strategies. 
  • ABO blood group and bleeding after coronary artery bypass graft surgery. 
  • ANTARCTIC: platelet function testing to adjust therapy. 
  • Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. 
  • Acetylation phenotype, platelet monoamine oxidase inhibition, and the effectiveness of phenelzine in depression. 
  • Acetylsalicylic acid and clopidogrel hyporesponsiveness following acute coronary syndromes. 
  • Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. 
  • Activation of protein kinase C by oleic acid. Determination and analysis of inhibition by detergent micelles and physiologic membranes: requirement for free oleate. 
  • Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. 
  • Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. 
  • Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. 
  • Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet alpha 2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. 
  • Adrenergic receptors. 
  • Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. 
  • Affinity chromatography of human platelet alpha 2-adrenergic receptors. 
  • Agonist interactions with alpha-adrenergic receptors. 
  • Agonist versus antagonist binding to alpha-adrenergic receptors. 
  • Agonist-specific effects of guanine nucleotides on alpha-adrenergic receptors in human platelets. 
  • Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets. 
  • Alpha-adducin dissociates from F-actin and spectrin during platelet activation. 
  • Alpha-adrenergic receptor subtypes: quantitative assessment by ligand binding. 
  • An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation. 
  • Analysis of sphingoid bases and sphingoid base 1-phosphates by high-performance liquid chromatography. 
  • Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. 
  • Antibody-Armed Platelets for the Regenerative Targeting of Endogenous Stem Cells. 
  • Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor. 
  • Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. 
  • Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. 
  • Antiplatelet therapy and platelet function testing. Introduction. 
  • Arylazide photoaffinity probe for alpha 2-adrenoceptors. 
  • Aspirin and bleeding after coronary artery bypass grafting. 
  • Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function. 
  • Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. 
  • Aspirin resistance and a single gene. 
  • Aspirin resistance. 
  • Aspirin resistance: position paper of the Working Group on Aspirin Resistance. 
  • Assessing the current role of platelet function testing. 
  • Assessment of oral antithrombotic therapy by platelet function testing. 
  • Assessment of platelet activity by measuring platelet-derived substances in plasma from patients with acute myocardial infarction: surprising lessons from the GUSTO-III Platelet Study. 
  • Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. 
  • Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease. 
  • Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. 
  • Autocrine-paracrine mechanisms of vascular myocytes in systemic hypertension. 
  • Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. 
  • Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13. 
  • Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. 
  • Beyond thrombosis: the versatile platelet in critical illness. 
  • Bioenergetic Differences in the Airway Epithelium of Lean Versus Obese Asthmatics Are Driven by Nitric Oxide and Reflected in Circulating Platelets. 
  • Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. 
  • Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. 
  • Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. 
  • Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. 
  • CD40L expression in plasma of volunteers following LPS administration: A comparison between assay of CD40L on platelet microvesicles and soluble CD40L. 
  • Captopril-enhanced binding of PlA1 (HPA-1a) antibodies in posttransfusion purpura. 
  • CardioPulse: Platelet inhibitors and their differences. 
  • Cardiopulmonary bypass induces leukocyte-platelet adhesion. 
  • Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. 
  • Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. 
  • Characteristics of norepinephrine and clonidine displacement of [3H]yohimbine binding to platelet alpha2-adrenoreceptors in healthy volunteers. 
  • Characterization of G25K, a GTP-binding protein containing a novel putative nucleotide binding domain. 
  • Cigarette smoking and clopidogrel interaction. 
  • Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. 
  • Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. 
  • Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists. 
  • Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. 
  • Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. 
  • Clopidogrel resistance: implications for coronary stenting. 
  • Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. 
  • Coagulation factor interaction with platelets. 
  • Coated platelet assay: a feasible approach to a complicated science. 
  • Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection? 
  • Combining necrosis and platelet markers for perfecting myocardial infarction rule out: how close are we? 
  • Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets. 
  • Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. 
  • Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. 
  • Comparison of the platelet activation status of single-donor platelets obtained with two different cell separator technologies. 
  • Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. 
  • Conditions influencing the interaction of asialo von Willebrand factor with human platelets--the effects of external ionized calcium concentration and the role of arachidonate pathway. 
  • Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. 
  • Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. 
  • Contact x-ray microscopy. A new technique for imaging cellular fine structure. 
  • Contribution of platelets, the coagulation and fibrinolytic systems to cutaneous wound healing. 
  • Cross-linking of fibrin by fibrin=stabilizing factor. 
  • Cyclic nucleotides regulate the morphologic alterations required for chemotaxis in monocytes. 
  • Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. 
  • Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. 
  • Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation. 
  • Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets. 
  • Deoxycholate induces the preferential hydrolysis of polyphosphoinositides by human platelet and rat corneal phospholipase C. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. 
  • Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. 
  • Detection of bacterial contamination in apheresis platelets: is apheresis technology a factor? 
  • Detection of platelet isoantibodies by (3H)serotonin platelet release and its clinical application to the problem of platelet matching. 
  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. 
  • Development of an affinity ligand for purification of alpha 2-adrenoceptors from human platelet membranes. 
  • Dexamethasone suppression test identifies a subset of elderly depressed patients with reduced platelet serotonin transport and resistance to imipramine inhibition of transport. 
  • Diagnostics for aspirin resistance. 
  • Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. 
  • Different sedimentation properties of agonist- and antagonist-labelled platelet alpha 2 adrenergic receptors. 
  • Differential effects of cytochalasin B on platelet release, aggregation and contractility: evidence against a contractile mechanism for the release of platelet granular contents. 
  • Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel. 
  • Differential regulation of the alpha 2-adrenergic receptor by Na+ and guanine nucleotides. 
  • Disseminated intravascular coagulation and renal failure: Production in the monkey with autologous red blood cell stroma. 
  • Do glucocorticoids contribute to the abnormalities in serotonin transporter expression and function seen in depression? An animal model. 
  • Does increased platelet release of Abeta peptide contribute to brain abnormalities in individuals with depression? 
  • Does maternal platelet-associated or platelet-bindable IgG correlate with levels in umbilical cord blood or colostrum during normal pregnancy? 
  • Dual islet transplantation modeling of the instant blood-mediated inflammatory reaction. 
  • Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. 
  • Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. 
  • Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. 
  • Early deaths in newly diagnosed cases of pediatric acute leukemia: a Southwest Oncology Group Study. 
  • Editor's page: fundamentals in neurocardiology: the brain-platelet-coronary artery interface. 
  • Editorial: platelet transfusions in cirrhosis-do the risks outweigh the unclear benefits? 
  • Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. 
  • Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). 
  • Effect of Mts1 on the structure and activity of nonmuscle myosin II. 
  • Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. 
  • Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. 
  • Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation. 
  • Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. 
  • Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. 
  • Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). 
  • Effect of lipopolysaccharide administration on the number, phenotype and content of nuclear molecules in blood microparticles of normal human subjects. 
  • Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. 
  • Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. 
  • Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. 
  • Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. 
  • Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. 
  • Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. 
  • Effects of 9, 12, 15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on platelet aggregation. 
  • Effects of 9,12,15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on the platelet aggregation. 
  • Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. 
  • Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. 
  • Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. 
  • Endothelial denudation and myointimal thickening in the rat carotid artery induced by the passage of bubbles. 
  • Endotoxin induces PAF production in the rat ileum: quantitation of tissue PAF by an improved method. 
  • Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. 
  • Ether lipid metabolism by AADACL1 regulates platelet function and thrombosis. 
  • Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. 
  • Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage. 
  • Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. 
  • Evaluation of hemostasis by the Clot Signature Analyzer: a potentially valuable device for the anesthesiologist. 
  • Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance': a rebuttal. 
  • Expanding the platelet inventory to mitigate the impact of severe shortages. 
  • Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. 
  • Expression of three alpha 2-adrenergic receptor subtypes in rat tissues: implications for alpha 2 receptor classification. 
  • Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. 
  • Factor VIII/von Willebrand protein. Modification of its carbohydrate causes reduced binding to platelets. 
  • Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. 
  • Factors influencing survival in pediatric acute leukemia. The SWCCSG experience, 1958-1970. 
  • Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. 
  • Fibronectin isoforms in megakaryocytes. 
  • Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. 
  • Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets. 
  • G-protein-coupled receptors as signaling targets for antiplatelet therapy. 
  • G-protein-coupled receptors signaling pathways in new antiplatelet drug development. 
  • Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction. 
  • Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. 
  • Genome sequencing unveils a regulatory landscape of platelet reactivity. 
  • Genome-Wide Association Study Links Receptor Tyrosine Kinase Inhibitor Sprouty 2 to Thrombocytopenia after Coronary Artery Bypass Surgery. 
  • Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. 
  • Glutathione peroxidase-3 deficiency promotes platelet-dependent thrombosis in vivo. 
  • Glutathione reductases from a variety of sources are inhibited by physiological levels of glutathione. 
  • Glycoprotein IIb/IIIa integrin blockade. 
  • Graft-v-host disease is associated with autoimmune-like thrombocytopenia. 
  • Growth factors modulate gonadotropin receptor induction in granulosa cell cultures. 
  • HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm. 
  • Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. 
  • Heparin Resistance - Clinical Perspectives and Management Strategies. 
  • Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. 
  • Heparin neutralization by recombinant platelet factor 4 and protamine. 
  • Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. 
  • Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. 
  • Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. 
  • Heterogeneity of radioligand binding to alpha-adrenergic receptors. Analysis of guanine nucleotide regulation of agonist binding in relation to receptor subtypes. 
  • High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases. 
  • High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? 
  • High-dose intravenous immunoglobulin for severe platelet alloimmunization. 
  • High-throughput acoustic separation of platelets from whole blood. 
  • Hormonal inhibition of adenylate cyclase. alpha 2 Adrenergic receptors promote release of [3H]guanylylimidodiphosphate from platelet membranes. 
  • Hormone-sensitive adenylate cyclase. Delineation of a trypsin-sensitive site in the pathway of receptor-mediated inhibition. 
  • Hostility and platelet reactivity in individuals without a history of cardiovascular disease events. 
  • Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. 
  • Human erythrocyte myosin: identification and purification. 
  • Human mononuclear phagocyte transglutaminase activity cross-links fibrin. 
  • Human platelet adenylate cyclase: delineation of distinct stimulatory and inhibitory guanine nucleotide regulatory pathways. 
  • Human platelet-derived growth factor preparations contain a separate activity which potentiates follicle-stimulating hormone-mediated induction of luteinizing hormone receptor in cultured rat granulosa cells: evidence for transforming growth factor-beta. 
  • Human platelets activate porcine endothelial cells through a CD154-dependent pathway. 
  • Human platelets exhibit chemotaxis using functional N-formyl peptide receptors. 
  • Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity. 
  • Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. 
  • Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. 
  • Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. 
  • IVIG therapy in neonatal isoimmune thrombocytopenic purpura and alloimmunization thrombocytopenia. 
  • Identification of alpha-adrenergic receptors in human platelets by [3H]dihydroergocryptine binding. 
  • Identification of the ral and rac1 gene products, low molecular mass GTP-binding proteins from human platelets. 
  • Identification of the subunit-binding site of alpha 2-adrenergic receptors using [3H]phenoxybenzamine. 
  • Identification, partial purification, and characterization of a novel phospholipid-dependent and fatty acid-activated protein kinase from human platelets. 
  • Immune fever in the rabbit: responses of the hematologic and complement systems. 
  • Immune hemolytic transfusion reactions in monkeys: activation of the kallikrein system. 
  • Immunologic studies before and after splenectomy in a patient with the Wiskott-Aldrich syndrome. 
  • Immunoreactive forms of human erythrocyte ankyrin are present in diverse cells and tissues. 
  • Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. 
  • Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. 
  • Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. 
  • Improving endothelial cell adhesion to vascular graft surfaces: clinical need and strategies. 
  • In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets. 
  • In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. 
  • In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. 
  • In vitro preparation of nonenzymatically glucosylated human transferrin, alpha 2-macroglobulin, and fibrinogen with preservation of function. 
  • In-111 platelet scintigraphy: carotid atherosclerosis and stroke. 
  • Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. 
  • Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. 
  • Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. 
  • Indium-111 platelet scintigraphy in cerebrovascular disease. 
  • Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. 
  • Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. 
  • Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. 
  • Inhibited and Uninhibited Platelet Deposition Within a Thrombus: Does It Depend on the Antiplatelet Drug? 
  • Inhibition of platelet monoamine oxidase in depressed subjects treated with phenelzine. 
  • Inhibitory effect of ristocetin and factor VIII/von Willebrand factor protein on human platelet adenylate cyclase activity. 
  • Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. 
  • Insignificant blood damage in calves with a total artificial heart up to six months. 
  • Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation. 
  • Interactions of agonists with platelet alpha 2-adrenergic receptors. 
  • Interference of chylomicrons in analysis of platelets by flow cytometry. 
  • Intracellular communication and immunothrombosis in sepsis. 
  • Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. 
  • Intratumoral consumption of indium-111 labeled platelets in a patient with hemangiomatosis and intravascular coagulation (Kasabach-Merritt syndrome). 
  • Investigating the mechanisms of hyporesponse to antiplatelet approaches. 
  • Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy? 
  • Isoantibody specificity in post-transfusion purpura. 
  • LAT is required for tyrosine phosphorylation of phospholipase cgamma2 and platelet activation by the collagen receptor GPVI. 
  • LW protein: a promiscuous integrin receptor activated by adrenergic signaling. 
  • Lack of efficacy for conventional gamma irradiation of platelet concentrates to abrogate bacterial growth. 
  • Lectin and epidermal growth factor domains of P-selectin at physiologic density are the recognition unit for leukocyte binding. 
  • Local drug delivery of argatroban from a polymeric-metallic composite stent reduces platelet deposition in a swine coronary model. 
  • Localization of the fourth membrane spanning domain as a ligand binding site in the human platelet alpha 2-adrenergic receptor. 
  • Longitudinal RNA-Seq Analysis of the Repeatability of Gene Expression and Splicing in Human Platelets Identifies a Platelet SELP Splice QTL. 
  • Loss of the cytoskeletal protein Pdlim7 predisposes mice to heart defects and hemostatic dysfunction. 
  • Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity. 
  • MAO inhibition and control of anxiety following amitriptyline therapy. A pilot study. 
  • Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. 
  • Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases. 
  • Mapping of a ligand-binding site for the human thromboxane A2 receptor protein. 
  • Marked reduction in the number of platelet-tritiated imipramine binding sites in geriatric depression. 
  • Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. 
  • Mean platelet volume improves upon the megathrombocyte index but cannot replace the blood film examination in the evaluation of thrombocytopenia. 
  • Mediators of pulmonary injury induced by inhalation of bacterial endotoxin. 
  • Membrane protein mediation of thromboxane A2-induced platelet aggregation. 
  • Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. 
  • Metabolic requirements of contractile force generation in platelet rich plasma - a rheological study. 
  • Microparticles in cardiovascular disease pathophysiology and outcomes. 
  • Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. 
  • Modeling deterministic effects in hematopoietic system caused by chronic exposure to ionizing radiation in large human cohorts. 
  • Modeling hematopoietic system response caused by chronic exposure to ionizing radiation. 
  • Modulation of platelet shape and membrane receptor binding by Ca2+-calmodulin complex. 
  • Molecular pharmacology of adenylate cyclase-coupled alpha- and beta-adrenergic receptors. 
  • Morphometric changes of the lung induced by inhaled bacterial endotoxin. 
  • Multiple effects of guanine nucleotides on human platelet adenylated cyclase. 
  • Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. 
  • NEDD9 Is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation. 
  • Nanosilver composite pNIPAm microgels for the development of antimicrobial platelet-like particles. 
  • Neonatal Alloimmune Thrombocytopenia: A Concise Review. 
  • Neonatal alloimmune thrombocytopenic purpura. 
  • Neonatal alloimmune thrombocytopenic purpura: a case report. 
  • Normal platelet mitochondrial complex I activity in Huntington's disease. 
  • Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. 
  • Nox2 NADPH oxidase is dispensable for platelet activation or arterial thrombosis in mice. 
  • One more way that mice and men are different. 
  • Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. 
  • Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. 
  • Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. 
  • P-Selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver. 
  • PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. 
  • PAS-C platelets contain less plasma protein, lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets. 
  • Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review. 
  • Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies. 
  • Patterns of platelet response in idiopathic TTP/HUS: frequency of declining platelet counts with plasma exchange and the recognition and significance of a pseudo refractory state. 
  • Peripheral serotonin causes dengue virus-induced thrombocytopenia through 5HT2 receptors. 
  • Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. 
  • Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. 
  • Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. 
  • Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). 
  • Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. 
  • Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. 
  • Phosphoinositides of sheep platelets plasma membranes. 
  • Phosphorylation of Gz in human platelets. Selectivity and site of modification. 
  • Photoaffinity labeling of human platelet and rabbit kidney alpha 2-adrenoceptors with [3H]SKF 102229. 
  • Plasma thrombopoietic activity in humans with normal and abnormal platelet counts. 
  • Plasma thrombospondin as an indicator of intravascular platelet activation in patients with vasculitis. 
  • Plastic-based acoustofluidic devices for high-throughput, biocompatible platelet separation. 
  • Platelet MAO activity in posttraumatic stress disorder. 
  • Platelet MAO inhibition following tricyclic antidepressant therapy. 
  • Platelet RNA as a novel biomarker for the response to antiplatelet therapy. 
  • Platelet Reactivity and Coagulation Markers in Patients with COVID-19. 
  • Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. 
  • Platelet [3H]-imipramine binding and leukoencephalopathy in geriatric depression. 
  • Platelet activation after stenting with heparin-coated versus noncoated stents. 
  • Platelet activation and its patient-specific consequences. 
  • Platelet activation in patients with thrombotic thrombocytopenic purpura. 
  • Platelet activity of high-dose factor VIIa is independent of tissue factor. 
  • Platelet adhesion on a bioresorbable poly(propylene fumarate-co-ethylene glycol) copolymer. 
  • Platelet alpha 2-adrenergic receptors in schizophrenic patients before and after phenothiazine treatment. 
  • Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: a preliminary study. 
  • Platelet alpha2-adrenergic receptor coupling efficiency to Gi protein in subjects with post-traumatic stress disorder and normal controls. 
  • Platelet alpha2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome. 
  • Platelet and fibrin modification by radiographic contrast media. 
  • Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). 
  • Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. 
  • Platelet binding and activity of recombinant factor VIIa. 
  • Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. 
  • Platelet biology for the clinician-scientist: an evolution of understanding. 
  • Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. 
  • Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. 
  • Platelet function and fibrinolytic agents: two sides of a coin? 
  • Platelet function and pharmacologic inhibition. 
  • Platelet function and total length of intracoronary stents: is there a correlation? 
  • Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y₁₂ inhibitor therapeutic window. 
  • Platelet functions beyond hemostasis. 
  • Platelet gamma-aminobutyrate-alpha-ketoglutarate transaminase (GABA-T) in schizophrenia. 
  • Platelet glutathione transport: characteristics and evidence for regulation by intraplatelet thiol status. 
  • Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. 
  • Platelet hyaluronidase-2: an enzyme that translocates to the surface upon activation to function in extracellular matrix degradation. 
  • Platelet inhibition by low-dose aspirin is not influenced by body mass or weight. 
  • Platelet microparticle delivered microRNA-Let-7a promotes the angiogenic switch. 
  • Platelet microparticles: making blood a bad humor. 
  • Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism. 
  • Platelet monitoring for PCI: is it really necessary? 
  • Platelet monoamine oxidase activity in schizophrenia. 
  • Platelet procoagulant complex assembly in a tissue factor-initiated system. 
  • Platelet reactivity and thrombogenicity in postmenopausal women. 
  • Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. 
  • Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans. 
  • Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. 
  • Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation. 
  • Platelet response in practice: Applying new insights and tools for testing and treatment. 
  • Platelet transfusion reactions: febrile nonhemolytic reaction or bacterial contamination? Diagnosis, detection, and current preventive modalities. 
  • Platelet uptake of the pheochromocytoma-scanning agent 131I-meta-iodobenzylguanadine. 
  • Platelet-Mediated Thrombosis: From Bench to Bedside. 
  • Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. 
  • Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. 
  • Platelet-dependent action of high-dose factor VIIa. 
  • Platelet-derived CD154: ultrastructural localization and clinical correlation in organ transplantation. 
  • Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. 
  • Platelet-like particles improve fibrin network properties in a hemophilic model of provisional matrix structural defects. 
  • Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. 
  • Platelet-rich plasma: a biomimetic approach to enhancement of surgical wound healing. 
  • Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. 
  • Platelets and thrombin generation. 
  • Platelets contain releasable coagulation factor IX antigen. 
  • Platelets contain releasable coagulation factor IX antigen: response. 
  • Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. 
  • Platelets from genome to proteome and beyond. 
  • Platelets from thrombocytopenic ponies acutely infected with equine infectious anemia virus are activated in vivo and hypofunctional. 
  • Platelets in atherothrombosis. 
  • Platelets induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic rat liver. 
  • Platelets influence vascularized organ transplants from start to finish. 
  • Platelets promote pulmonary pull of polys. 
  • Platelets trigger perivascular mast cell degranulation to cause inflammatory responses and tissue injury. 
  • Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. 
  • Point of care devices for assessing bleeding and coagulation in the trauma patient. 
  • Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. 
  • Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. 
  • Possible prorenin activating mechanisms in the blood vessel wall. 
  • Precatheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry®. 
  • Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. 
  • Preferential uncoupling by manganese of alpha adrenergic receptor mediated inhibition of adenylate cyclase in human platelets. 
  • Preliminary observations on abnormalities of membrane structure and function in essential hypertension. 
  • Pretreatment with an inhibitor of mac-1 alters regional and systemic platelet function during ischemia-reperfusion in swine. 
  • Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. 
  • Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. 
  • Prognostic implications for direct platelet-associated IgG in childhood idiopathic thrombocytopenic purpura. 
  • Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase. 
  • Protamine-induced immune thrombocytopenia. 
  • Protein kinase C: cellular target of the second messenger arachidonic acid? 
  • Purification and characterization of papain-solubilized HLA antigens from human platelets. 
  • Purification and characterization of the human platelet alpha 2-adrenergic receptor. 
  • Purification and subunit structure of human plasma and platelet fibrin-stabilizing factor. 
  • Radioenzymatic assay of platelet serotonin, dopamine and norepinephrine in subjects with normal and increased serotonin production. 
  • Recent advances in the research and management of sepsis-associated DIC. 
  • Receptor-mediated modulation of human monocyte, neutrophil, lymphocyte, and platelet function by phorbol diesters. 
  • Reduced inhibitory effect of imipramine on radiolabeled serotonin uptake into platelets in geriatric depression. 
  • Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. 
  • Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. 
  • Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. 
  • Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. 
  • Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy. 
  • Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. 
  • Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo. 
  • Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers. 
  • Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. 
  • Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. 
  • Remodeling the blood coagulation cascade. 
  • Response of blood leukocytes to thrombin receptor peptides. 
  • Response variability and the role of platelet function testing. 
  • Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. 
  • Rethinking the coagulation cascade. 
  • Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: an aid in assessing marrow recovery. 
  • Retroviral vector-mediated gene transfer into umbilical cord blood-derived megakaryocyte and platelet progenitors. 
  • Risk of heparin-induced thrombocytopenia from heparin-bonded vascular prostheses. 
  • Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. 
  • Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. 
  • Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. 
  • S-nitrosoglutathione/glutathione disulphide/Cu2+-dependent stimulation of L-arginine transport in human platelets. 
  • SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. 
  • Scintigraphic detection of platelet deposition in atherosclerotic macaques: a new technique for investigation of antithrombotic drugs. 
  • Selectins: a family of adhesion receptors. 
  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. 
  • Selective regulation of protein kinase C isoenzymes by oleic acid in human platelets. 
  • Selectivity of dobutamine for adrenergic receptor subtypes: in vitro analysis by radioligand binding. 
  • Septic risk increases with apheresis platelet storage time. 
  • Serotonin transporter expression in rat brain regions and blood platelets: aging and glucocorticoid effects. 
  • Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study. 
  • Significance of complement to the mechanism of action of endotoxin. 
  • Silencing Porcine CMAH and GGTA1 Genes Significantly Reduces Xenogeneic Consumption of Human Platelets by Porcine Livers. 
  • Single case study. Complementary effects of phenelzine and psychotherapy in long term treatment of depression. 
  • Smoking and cardiovascular diseases: paradox greater than expected? 
  • Smooth muscle cell proliferation in the occluded rat carotid artery: lack of requirement for luminal platelets. 
  • Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group. 
  • Sonorheometry assessment of platelet function in cardiopulmonary bypass patients: Correlation of blood clot stiffness with platelet integrin αIIbβ3 activity, aspirin usage, and transfusion risk. 
  • Species differences in alpha 2-adrenergic regulation of platelet adenylate cyclase. 
  • Structure of human platelet membrane glycoproteins IIb and IIIa as determined by electron microscopy. 
  • Substituted 1,3-Dihydro-2H-pyrrolo-[2,3-b]pyridin-2-ones as Potential Antiinflammatory Agents 
  • Substrate-dependent activation energy of the reaction catalyzed by monoamine oxidase. 
  • Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets. 
  • Synergism between platelets and leukocytes in inducing endothelial cell apoptosis in the cold ischemic rat liver: a Kupffer cell-mediated injury. 
  • Synthesis and biological characterization of sqbazide, a novel biotinylated photoaffinity probe for the study of the human platelet thromboxane A2 receptor. 
  • Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. 
  • TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. 
  • TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation. 
  • Targeted anti-IL-1β platelet microparticles for cardiac detoxing and repair. 
  • The Cutaneous Wound Innate Immunological Microenvironment. 
  • The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. 
  • The anti-inflammatory actions of platelet endothelial cell adhesion molecule-1 do not involve regulation of endothelial cell NF-kappa B. 
  • The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. 
  • The biochemistry of haemostasis. 
  • The bleeding diathesis in human glycogen storage disease type I: in vitro identification of a naturally occurring inhibitor of ristocetin-induced platelet aggregation. 
  • The central role of thrombin in bleeding disorders. 
  • The coagulation cascade in cirrhosis. 
  • The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The effect of isocarboxazid on platelet MAO activity. 
  • The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation. 
  • The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. 
  • The effect of temperature variation in vitro on platelet-leukocyte interactions and individual prothrombotic potential. 
  • The effects of argatroban on thrombin generation and hemostatic activation in vitro. 
  • The effects of milrinone on platelets in patients undergoing cardiac surgery. 
  • The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers. 
  • The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. 
  • The evolution of platelet-directed pharmacotherapy. 
  • The expression of microvesicles in the blood of patients with Graves' disease and its relationship to treatment. 
  • The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. 
  • The fate of human platelets exposed to porcine renal endothelium: a single-pass model of platelet uptake in domestic and genetically modified porcine organs. 
  • The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain: are we comparing apples with oranges. 
  • The hemodynamics of thrombus formation in arteries. 
  • The importance of dose in isocarboxazid therapy. 
  • The influence of red wine or white wine intake on platelet function and viscoelastic property of blood in volunteers. 
  • The pharmacogenetics of antiplatelet agents: towards personalized therapy? 
  • The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. 
  • The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. 
  • The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. 
  • The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. 
  • The relationship of complement consumption to immune fever. 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The role of ligand-ligand interactions in competition by fibrinogen and fibrin degradation products for fibrinogen binding to human platelets. 
  • The role of platelets on regenerating liver: Thoughts beyond parenchymal proliferation. 
  • The role of soluble components in ambient fine particles-induced changes in human lungs and blood. 
  • The role of the porcine von Willebrand factor: baboon platelet interactions in pulmonary xenotransplantation. 
  • The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. 
  • The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). 
  • The use of in vitro technics to study drug-induced pancytopenia. 
  • Therapeutic white blood cell and platelet depletions using the spectra OPTIA system continuous mononuclear cell protocol. 
  • Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. 
  • Thrombin activates factor XI on activated platelets in the absence of factor XII. 
  • Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis. 
  • Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. 
  • Thrombocyte Inhibition Restores Protective Immunity to Mycobacterial Infection in Zebrafish. 
  • Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. 
  • Thrombus imaging with indium-111 platelets. 
  • Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. 
  • Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. 
  • Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. 
  • Transcription Factor RUNX1 Regulates Platelet PCTP (Phosphatidylcholine Transfer Protein): Implications for Cardiovascular Events: Differential Effects of RUNX1 Variants. 
  • Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. 
  • Translation and Clinical Development of Antithrombotic Aptamers. 
  • Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? 
  • Treatment of platelet alloimmunization with intravenous immunoglobulin. Two case reports and review of the literature. 
  • Trends in platelet distributions from 2008 to 2017: a survey of twelve national and regional blood collectors. 
  • Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. 
  • Update on multi-center clinical trials in the United States. 
  • Uptake of serotonin into rat platelets and synaptosomes: comparative structure-activity relationships, energetics and evaluation of the effects of acute and chronic nortriptyline administration. 
  • Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia. 
  • Use of common antiplatelet drugs for vascular diseases. 
  • Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department. 
  • Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity. 
  • Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma. 
  • Validated model of platelet slip at stenosis and device surfaces. 
  • Validation of the dual radiotracer method for quantitative In-111 platelet scintigraphy. 
  • Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. 
  • Variation in the level of xenoantigen expression in porcine organs. 
  • Vascular wall renin-angiotensin pathway in control of the circulation. A hypothesis. 
  • Vincristine therapy for severe platelet alloimmunization. 
  • Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. 
  • Warming Up to Cold-stored Platelets. 
  • We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity. 
  • YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. 
  • Zinc and immunocompetence in elderly people: effects of zinc supplementation for 3 months. 
  • Zinc and immunocompetence in the elderly: baseline data on zinc nutriture and immunity in unsupplemented subjects. 
  • [Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome]. 
  • [Problem of neuronal reception and the dopamine hypothesis of schizophrenia]. 
  • eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation in vitro. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Arepally, Gowthami Morey, Professor of Medicine, Pathology
  • Bennett, Vann, George Barth Geller Distinguished Professor of Molecular Biology, Duke Cancer Institute
  • Chen, Jun, Professor of Medicine, Duke Cancer Institute
  • Erickson, Harold Paul, James B. Duke Distinguished Professor Emeritus, Cell Biology
  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Hoffman, Maureane, Professor of Pathology, Integrative Immunobiology
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine